---
title: "Comorbidity Risk Score from 13 Million Records Predicts COVID-19 Hospitalisation and Common Diseas"
id: "medrxiv-7-predicting-covid-19-hospitalisation-and-common-disease-risk-from-comorbid"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-7-predicting-covid-19-hospitalisation-and-common-disease-risk-from-comorbid"
content_type: "clinical_feed_article"
specialty: "Infectious Disease"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.08.27.26361302v1?rss=1"
published_at: "2026-09-01T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Comorbidity Risk Score from 13 Million Records Predicts COVID-19 Hospitalisation and Common Diseas
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-7-predicting-covid-19-hospitalisation-and-common-disease-risk-from-comorbid
- **Specialty:** [Infectious Disease](https://medichelpline.com/clinical-feed/infectious-disease.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.08.27.26361302v1?rss=1)
- **Published At:** 2026-09-01T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- Researchers developed the **Comorbidity Risk Score (CRS)** using linked electronic health records for 13 million individuals aged 40–69 across England to predict **COVID-19 hospitalisation** and 87 other disease outcomes. - CRS estimated conditional effects of 212 prior diagnoses on 88 outcomes, providing interpretable, diagnosis-level contributions to disease risk. - Effect-size correlations between outcomes derived from CRS closely matched genetic correlations (example: myocardial infarction vs hyperlipidaemia: CRS correlation 0.76, genetic correlation 0.79), supporting that comorbidity architectures map disease aetiology. - CRS identified about 5% of the population with an average 3.4-fold higher risk for the studied outcomes; specific excess risks included myocardial infarction (4.4-fold), lung cancer (6.5-fold), and COVID-19 hospitalisation (6.3-fold). - Using only prior diagnoses, CRS outperformed state-of-the-art clinical COVID-19 prediction models and substantially outperformed previously reported AI and linear models trained on ~0.5 million individuals, suggesting larger training sample size can outweigh model complexity. - CRS showed near-perfect transferability across self-reported ethnicities (example: AUROC ratio Black vs White = 97.3%), indicating consistent predictive performance across groups. - The method differentiated independently predictive comorbidities from indirect associations; for example, lipid metabolism disorder predicted myocardial infarction but not ischaemic stroke after conditioning on other diagnoses. - Data access and approvals: research used anonymised NHS England SDE data accessed under approvals from the Advisory Group for Data and the CVD-COVID-UK/COVID-IMPACT Approvals & Oversight Board; data are available to accredited researchers via national custodian application processes. - Ethical and reporting compliance were declared, with IRB/oversight approvals reported and no competing interests declared.
## Clinical Analysis & Structured Key Points
[](https://www.medrxiv.org/cdn-cgi/content?id=rungdvipQ1Kkr6YX5w9W9M_raM1Xc7xmDkpyEhKoABg-1788289514.306655-1.2.1.1-cErLiPJUSgVOBdcEaiSGsuyAezm.3iGTfMXh3xkWi1NMMhMbOpsVpZiooo9Gp_Ze) [Skip to main content](https://www.medrxiv.org/content/10.64898/2026.08.27.26361302v1?rss=1#main-content) [![medRxiv](https://www.medrxiv.org/sites/default/files/medrxiv_inner_logo.png)](https://www.medrxiv.org/) * [Home](https://www.medrxiv.org/) * [Submit](https://www.medrxiv.org/submit-a-manuscript) * [FAQ](https://www.medrxiv.org/about/FAQ) * [Blog](https://connect.medrxiv.org/news/) * [ALERTS / RSS](https://www.medrxiv.org/content/alertsrss) * [Resources](https://connect.medrxiv.org/resources/) * [About](https://www.medrxiv.org/content/about-medrxiv) Search for this keyword [Advanced Search](https://www.medrxiv.org/search) Follow this preprint # Predicting COVID-19 hospitalisation and common disease risk from comorbid diagnoses in 13 million individuals [ View ORCID Profile](http://orcid.org/0000-0003-4845-5170)Hongjiao Liu, [ View ORCID Profile](http://orcid.org/0000-0002-2441-895X)Mehrdad A. Mizani, [ View ORCID Profile](http://orcid.org/0009-0009-1472-3959)Yujie Zhao, Angela Wood, [ View ORCID Profile](http://orcid.org/0000-0001-9413-6520)Michael Inouye, [ View ORCID Profile](http://orcid.org/0000-0002-2971-7975)Alkes L. Price, [ View ORCID Profile](http://orcid.org/0000-0001-6773-9182)Xilin Jiang, CVD-COVID-UK/COVID-IMPACT Consortium doi: https://doi.org/10.64898/2026.08.27.26361302 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Hongjiao Liu 1 British Heart Foundation Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Hongjiao%2BLiu%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Liu%20H&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AHongjiao%2BLiu%2B) * [ORCID record for Hongjiao Liu](http://orcid.org/0000-0003-4845-5170 "Open in new tab") Mehrdad A. Mizani 2 British Heart Foundation Data Science Centre, Health Data Research UK, London, UK; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Mehrdad%2BA.%2BMizani%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Mizani%20MA&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AMehrdad%2BA.%2BMizani%2B) * [ORCID record for Mehrdad A. Mizani](http://orcid.org/0000-0002-2441-895X "Open in new tab") Yujie Zhao 3 Institute of Science and Technology for Brain-Inspired Intelligence, Fudan University, Shanghai, China; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Yujie%2BZhao%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Zhao%20Y&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AYujie%2BZhao%2B) * [ORCID record for Yujie Zhao](http://orcid.org/0009-0009-1472-3959 "Open in new tab") Angela Wood 1 British Heart Foundation Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Angela%2BWood%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Wood%20A&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AAngela%2BWood%2B) Michael Inouye 1 British Heart Foundation Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Michael%2BInouye%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Inouye%20M&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AMichael%2BInouye%2B) * [ORCID record for Michael Inouye](http://orcid.org/0000-0001-9413-6520 "Open in new tab") Alkes L. Price 4 Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Alkes%2BL.%2BPrice%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Price%20AL&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AAlkes%2BL.%2BPrice%2B) * [ORCID record for Alkes L. Price](http://orcid.org/0000-0002-2971-7975 "Open in new tab") Xilin Jiang 1 British Heart Foundation Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Xilin%2BJiang%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Jiang%20X&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AXilin%2BJiang%2B) * [ORCID record for Xilin Jiang](http://orcid.org/0000-0001-6773-9182 "Open in new tab") * For correspondence: xj262@medschl.cam.ac.uk * [Abstract](https://www.medrxiv.org/content/10.64898/2026.08.27.26361302v1)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_art/node:1289758/1) * [Info/History](https://www.medrxiv.org/content/10.64898/2026.08.27.26361302v1.article-info)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_info/node:1289758/1) * [Metrics](https://www.medrxiv.org/content/10.64898/2026.08.27.26361302v1.article-metrics)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_metrics/node:1289758/1) * [Supplementary material](https://www.medrxiv.org/content/10.64898/2026.08.27.26361302v1.supplementary-material)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_data/node:1289758/1) * [Data/Code](https://www.medrxiv.org/content/10.64898/2026.08.27.26361302v1.external-links)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_data_code/node:1289758/1) * [ Preview PDF](https://www.medrxiv.org/content/10.64898/2026.08.27.26361302v1.full.pdf+html)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_pdf/node:1289758/1) ![Loading](https://www.medrxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif) ## Abstract Predicting disease risk from prior diagnoses is fundamental to clinical decision-making, particularly during health emergencies such as the COVID-19 pandemic, when individuals with long-term conditions may be disproportionately vulnerable to adverse outcomes. Despite intense interest in developing models to predict disease risk from prior diagnoses (1-3), most prediction models do not estimate effects of each prior diagnosis on disease risk conditional on other diagnoses, limiting interpretability and clinical utility. We developed the Comorbidity Risk Score (CRS), trained on 13 million individuals (age 40-69) from linked electronic health record (EHR) datasets of the entire population of England, to predict COVID-19 hospitalisation and 87 other disease outcomes. CRS was trained at close to saturated sample size and precisely estimated the effects of 212 prior diagnoses on the 88 disease outcomes, conditional on all other prior diagnoses. Correlations of CRS effect sizes across outcomes (e.g. 0.76 for myocardial infarction vs. hyperlipidaemia) matched the corresponding genetic correlations (e.g. 0.79 for myocardial infarction vs. hyperlipidaemia), confirming that comorbidity architectures capture disease aetiology. On average, CRS identified 5% of the population with 3.4-fold higher disease risk, including myocardial infarction (4.4-fold), lung cancer (6.5-fold), and COVID-19 hospitalisation (6.3-fold). Using prior diagnoses alone, CRS outperformed state-of-the-art clinical COVID-19 models (4). Furthermore, CRS (N=13 million) substantially outperformed state-of-the-art AI (1) (N=0.5 million) and linear (3) (N=0.5 million) models in predicting disease risk, suggesting that training sample size outweighs model complexity. CRS attained near-perfect transferability across self-reported ethnicities (e.g., Black vs. White: AUROC ratio = 97.3%). Finally, CRS distinguished independently predictive comorbidities from indirect associations, e.g., lipid metabolism disorder was a strong predictor of myocardial infarction risk but not ischaemic stroke, after conditioning on other prior diagnoses. In conclusion, CRS provides a comprehensive resource for understanding the impact of comorbidities on COVID-19 and other future diseases, revealing disease aetiology while enabling powerful prediction of disease risk. ### Competing Interest Statement The authors have declared no competing interest. ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: The CVD-COVID-UK/COVID-IMPACT research programme, led by the BHF Data Science Centre (https://bhfdatasciencecentre.org) received approval to access data in NHS England's SDE service for England from the Advisory Group for Data (AGD) (https://digital.nhs.uk/about-nhs-digital/corporate-information-and-documents/advisory-group-for-data) -- formerly the Independent Group Advising on the Release of Data (IGARD) -- via an application made in the Data Access Request Service (DARS) Online system (ref. DARS-NIC-381078-Y9C5K) (https://digital.nhs.uk/services/data-access-request-service-dars/dars-products-and-services). The CVD-COVID-UK/COVID-IMPACT Approvals & Oversight Board (https://bhfdatasciencecentre.org/areas/cvd-covid-uk-covid-impact/) subsequently granted approval to this project (CCU022) to access the data within NHS England's SDE service for England. The anonymised data used in this study were made available to accredited researchers only. Those wishing to gain access to the data should follow the application process of the relevant national data custodian. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes ## Data Availability The CVD-COVID-UK/COVID-IMPACT research programme, led by the BHF Data Science Centre (https://bhfdatasciencecentre.org) received approval to access data in NHS England's SDE service for England from the Advisory Group for Data (AGD) (https://digital.nhs.uk/about-nhs-digital/corporate-information-and-documents/advisory-group-for-data) -- formerly the Independent Group Advising on the Release of Data (IGARD) -- via an application made in the Data Access Request Service (DARS) Online system (ref. DARS-NIC-381078-Y9C5K) (https://digital.nhs.uk/services/data-access-request-service-dars/dars-products-and-services). The CVD-COVID-UK/COVID-IMPACT Approvals & Oversight Board (https://bhfdatasciencecentre.org/areas/cvd-covid-uk-covid-impact/) subsequently granted approval to this project (CCU022) to access the data within NHS England's SDE service for England. The anonymised data used in this study were made available to accredited researchers only. Those wishing to gain access to the data should follow the application process of the relevant national data custodian. ## Funder Information Declared Wellcome Trust, https://ror.org/029chgv08, 227566/Z/23/Z Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/). bioRxiv and medRxiv thank the following for their generous financial support: > The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, The University of Edinburgh, University of Washington, and Vrije Universiteit Amsterdam. [Donate to openRxiv ](https://www.zeffy.com/en-US/donation-form/donate-to-make-a-difference-10981) [ Back to top](https://www.medrxiv.org/content/10.64898/2026.08.27.26361302v1?rss=1#page) [ Previous](https://www.medrxiv.org/content/10.64898/2026.08.28.26361407v1 "VAGINAL STEAMING PRACTICES AMONG WOMEN AT MULAGO STI CLINIC, UGANDA: PREVALENCE, LACTOBACILLI PROPORTION DIFFERENCES, AND ASSOCIATED FACTORS.")[Next ](https://www.medrxiv.org/content/10.64898/2026.08.30.26361738v1 "Dynamic Clinical States and Transitions During the First 72 Hours of Intensive Care After Acute Stroke") Posted September 01, 2026. [ Download PDF](https://www.medrxiv.org/content/10.64898/2026.08.27.26361302v1.full.pdf) Print/Save Options [Download PDF](https://www.medrxiv.org/content/medrxiv/early/2026/09/01/2026.08.27.26361302.full.pdf)Full Text & In-line FiguresXML [More Info](https://www.medrxiv.org/about/FAQ#PrintOptions "More Information on Print/Save Options") [ Author Declarations](https://www.medrxiv.org/content/10.64898/2026.08.27.26361302v1#p-5) [Supplementary Material ](https://www.medrxiv.org/content/10.64898/2026.08.27.26361302v1.supplementary-material) [ Data/Code](https://www.medrxiv.org/content/early/2026/09/01/2026.08.27.26361302.external-links) [ Email](https://www.medrxiv.org/ "Email this Article") [ Share](https://www.medrxiv.org/) Predicting COVID-19 hospitalisation and common disease risk from comorbid diagnoses in 13 million individuals Hongjiao Liu, Mehrdad A. Mizani, Yujie Zhao, Angela Wood, Michael Inouye, Alkes L. Price, Xilin Jiang, CVD-COVID-UK/COVID-IMPACT Consortium medRxiv 2026.08.27.26361302; doi: https://doi.org/10.64898/2026.08.27.26361302 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Share This Article: Copy [![Twitter logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/twitter.png)](https://www.medrxiv.org/highwire_log/share/twitter?link=http%3A%2F%2Ftwitter.com%2Fshare%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.08.27.26361302v1%26text%3DPredicting%2520COVID-19%2520hospitalisation%2520and%2520common%2520disease%2520risk%2520from%2520comorbid%2520diagnoses%2520in%252013%2520million%2520individuals "Share this on Twitter") [![Facebook logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/fb-blue.png)](https://www.medrxiv.org/highwire_log/share/facebook?link=http%3A%2F%2Fwww.facebook.com%2Fsharer.php%3Fu%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.08.27.26361302v1%26t%3DPredicting%2520COVID-19%2520hospitalisation%2520and%2520common%2520disease%2520risk%2520from%2520comorbid%2520diagnoses%2520in%252013%2520million%2520individuals "Share on Facebook") [![LinkedIn logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/linkedin-32px.png)](https://www.medrxiv.org/highwire_log/share/linkedin?link=http%3A%2F%2Fwww.linkedin.com%2FshareArticle%3Fmini%3Dtrue%26url%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.08.27.26361302v1%26title%3DPredicting%2520COVID-19%2520hospitalisation%2520and%2520common%2520disease%2520risk%2520from%2520comorbid%2520diagnoses%2520in%252013%2520million%2520individuals%26summary%3D%26source%3DmedRxiv "Publish this post to LinkedIn") [![Mendeley logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/mendeley.png)](https://www.medrxiv.org/highwire_log/share/mendeley?link=http%3A%2F%2Fwww.mendeley.com%2Fimport%2F%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.08.27.26361302v1%26title%3DPredicting%2520COVID-19%2520hospitalisation%2520and%2520common%2520disease%2520risk%2520from%2520comorbid%2520diagnoses%2520in%252013%2520million%2520individuals "Share on Mendeley") [ Citation Tools](https://www.medrxiv.org/ "Citation Tools") [ Get QR code](https://connect.medrxiv.org/qr/2026.08.27.26361302) * [Tweet Widget](http://twitter.com/share?url=https%3A//www.medrxiv.org/content/10.64898/2026.08.27.26361302v1&count=horizontal&via=&text=Predicting%20COVID-19%20hospitalisation%20and%20common%20disease%20risk%20from%20comorbid%20diagnoses%20in%2013%20million%20individuals&counturl=www.medrxiv.org/content/10.64898/2026.08.27.26361302v1 "Tweet This") Reviews and Context 0 Comment 0 TRIP Peer Reviews 0 Community Reviews 0 Automated Services 0 Blogs/Media 0 Author Videos **Subject Areas** [**All Articles**](https://www.medrxiv.org/content/early/recent) * [Addiction Medicine](https://www.medrxiv.org/collection/addiction-medicine) (613) * [Allergy and Immunology](https://www.medrxiv.org/collection/allergy-and-immunology) (895) * [Anesthesia](https://www.medrxiv.org/collection/anesthesia) (326) * [Cardiovascular Medicine](https://www.medrxiv.org/collection/cardiovascular-medicine) (4768) * [Dentistry and Oral Medicine](https://www.medrxiv.org/collection/dentistry-and-oral-medicine) (474) * [Dermatology](https://www.medrxiv.org/collection/dermatology) (406) * [Emergency Medicine](https://www.medrxiv.org/collection/emergency-medicine) (643) * [Endocrinology (including Diabetes Mellitus and Metabolic Disease)](https://www.medrxiv.org/collection/endocrinology-including-diabetes-mellitus-and-metabolic-disease) (1613) * [Epidemiology](https://www.medrxiv.org/collection/epidemiology) (15832) * [Forensic Medicine](https://www.medrxiv.org/collection/forensic-medicine) (32) * [Gastroenterology](https://www.medrxiv.org/collection/gastroenterology) (1194) * [Genetic and Genomic Medicine](https://www.medrxiv.org/collection/genetic-and-genomic-medicine) (6982) * [
## Related Clinical Research

- [Neural-Immune-Cardiovascular Axis: Mechanisms and Therapeutic Targets in Cardiovascular Disease](https://medichelpline.com/clinical-feed/frontiers-in-immunology-13-neural-immune-cardiovascular-axis-from-mechanistic-crosstalk-to-therapeutic.md)
- [Recombinant shingles vaccine associated with reduced risk of cardiovascular events in older adults](https://medichelpline.com/clinical-feed/nature-2-recombinant-shingles-vaccination-and-the-risk-of-cardiovascular-events.md)
- [2026 ACC/AHA Dyslipidemia Guideline: Key implications for cholesterol and cardiovascular risk](https://medichelpline.com/clinical-feed/medical-news-today-0-is-your-cholesterol-too-high-per-the-new-acc-aha-guideline-5-things-to-know.md)
- [Post-acute and long-term cardiovascular effects after dengue infection: systematic review protocol](https://medichelpline.com/clinical-feed/plos-one-0-post-acute-and-long-term-cardiovascular-effects-following-dengue-infection-a.md)
- [Nicotine metabolism rate and myocardial infarction risk in people with HIV who smoke](https://medichelpline.com/clinical-feed/plos-one-12-rate-of-nicotine-metabolism-on-risk-of-myocardial-infarction-among-people-with.md)

## Navigation
- [← Back to Infectious Disease Feed](https://medichelpline.com/clinical-feed/infectious-disease.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.